Critical Analysis: Palisade Bio (NASDAQ:PALI) & Theravance Biopharma (NASDAQ:TBPH)

Palisade Bio (NASDAQ:PALI) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares Palisade Bio and Theravance Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250,000.00	874.84	-$16.78 million	($0.48)	-2.61
Theravance Biopharma	$104.31 million	8.48	$105.89 million	$1.01	16.86

Theravance Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palisade Bio and Theravance Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Volatility & Risk

Palisade Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Palisade Bio and Theravance Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1	0	8	2	3.00
Theravance Biopharma	0	7	0	0	2.00

Palisade Bio presently has a consensus target price of $9.29, suggesting a potential upside of 639.90%. Theravance Biopharma has a consensus target price of $19.00, suggesting a potential upside of 11.57%. Given Palisade Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Palisade Bio is more favorable than Theravance Biopharma.

Insider & Institutional Ownership

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 7.6% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Theravance Biopharma beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.